Pieris Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-based compensation (Tables)

Stock-based compensation (Tables)

6 Months Ended

Jun. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Total Stock-Based Compensation Expense Related to Share-Based Awards Under the Pieris Plan

Total stock-based compensation expense was recorded to operating expenses based upon the functional responsibilities of the individuals holding the respective options as follows:


	Three months ended June 30,				Six months ended June 30,
	2016		2015		2016		2015
Research and Development	$	175,498	$	78,348	$	301,939	$	129,185
General and administrative		436,347		189,691		678,290		356,189

Total stock-option expense	$	611,845	$	268,039	$	980,229	$	485,374

Schedule of Weighted-Average Assumptions Used for Calculating Value of Options Granted

The weighted-average fair value of the options granted during the three and six months ended June 30, 2015 was $1.81 and $1.82, respectively. The calculation was based on the following assumptions:


	Three months ended June 30,				Six months ended June 30,
	2016		2015		2016		2015
Dividend yield		0.0%		0.0%		0.0%		0.0%
Expected volatility		75.12% - 75.53%		73.43% - 75.07%		75.12% - 76.00%		73.43% - 75.07%
Weighted average risk-free interest rate		1.13% - 1.49%		1.49% - 1.79%		1.13% - 1.61%		1.49% - 1.79%
Expected term		5.0 - 5.7 years		5.3 - 5.8 years		5.0 - 5.7 years		5.3 - 5.8 years